Form 8-K - Current report:
SEC Accession No. 0001753926-25-001003
Filing Date
2025-06-25
Accepted
2025-06-25 15:14:40
Documents
14
Period of Report
2025-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084855_8k.htm   iXBRL 8-K 48303
2 EXHIBIT 99.1 g084855_ex99-1.htm EX-99.1 20649
3 EXHIBIT 99.2 g084855_ex99-2.htm EX-99.2 11775
  Complete submission text file 0001753926-25-001003.txt   261151

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lipo-20250625.xsd EX-101.SCH 3011
5 XBRL LABEL FILE lipo-20250625_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE lipo-20250625_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT g084855_8k_htm.xml XML 3899
Mailing Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208
Business Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208 412-901-0315
LIPELLA PHARMACEUTICALS INC. (Filer) CIK: 0001347242 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41575 | Film No.: 251073322
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)